|
|
Procept Biorobotics Corporation (NASDAQ: PRCT) |
|
Price: $20.6950
$-0.51 
-2.382%
|
| Day's High:
| $21.21500015258789
| Week Perf:
| -1.78 %
|
| Day's Low: |
$ 20.49 |
30 Day Perf: |
12.6 % |
| Volume (M): |
128,309 |
52 Wk High: |
$ 42.43 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$28.09 |
| Open: |
$21.15 |
52 Wk Low: |
$16.67 |
|
|
| Market Capitalization (Millions $) |
1,170 |
| Shares
Outstanding (Millions) |
57 |
| Employees |
888 |
| Revenues (TTM) (Millions $) |
321 |
| Net Income (TTM) (Millions $) |
-102 |
| Cash Flow (TTM) (Millions $) |
-71 |
| Capital Exp. (TTM) (Millions $) |
10 |
Business Description
Procept Biorobotics Corporation is a medical technology company that focuses on developing innovative medical devices to improve patient outcomes. The company primarily specializes in creating surgical robots and robotic systems for urological procedures. Procept Biorobotics' flagship product is the AquaBeam® Robotic System, which utilizes waterjet technology to remove tissue during surgery. The company's mission is to provide minimally invasive surgical solutions that enhance precision, decrease complications, and optimize patient recovery. Procept Biorobotics aims to revolutionize the field of urology by offering advanced robotic technologies that allow for more efficient and effective procedures.
Company Address: 150 Baytech Drive San Jose 95134 CA
Company Phone Number: 232-7200 Stock Exchange / Ticker: NASDAQ PRCT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Shares
Published Wed, Oct 30 2024 12:43 AM UTC
PROCEPT BioRobotics: A Surgical Robotics Player Gathers Momentum with Major Stock OfferingOn October 29, 2024, PROCEPT BioRobotics Corporation, based in San Jose, California and listed on NASDAQ under the ticker PRCT, announced the pricing of a significant underwritten public offering. The company intends to sell 1,923,076 shares of its common stock at a price of $91.00 per...
|
| Shares
Published Mon, Oct 28 2024 8:19 PM UTC
Procept BioRobotics Capitalizes on Strategic Expansion Amidst Breakthroughs in Urological TreatmentSan Jose, Calif. In a strategic move set to bolster its market presence, PROCEPT BioRobotics Corporation (NASDAQ: PRCT), a pioneering name in the realm of surgical robotics with a sharp focus on urological care, declares a public offering of $175 million in its common stock. ...
|
| Clinical Study
Published Mon, Oct 7 2024 8:04 PM UTC
In a significant advancement for prostate cancer treatment, PROCEPT BioRobotics Corporation has received U.S. Food and Drug Administration (FDA) approval to initiate a pivotal randomized clinical study assessing the safety and efficacy of Aquablation therapy in men diagnosed with localized prostate cancer, specifically those categorized within Grade Groups 1 to 3. This promi...
|
| Product Service News
Published Wed, Aug 21 2024 11:00 AM UTC
In a significant advancement for urological care, PROCEPT BioRobotics recently announced the FDA clearance of its HYDROS Robotic System. This system represents a cutting-edge, artificial intelligence-powered platform specifically designed to enhance the Aquablation Therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH). With a paradigm shift toward di...
|
| Product Service News
Published Mon, Jun 17 2024 8:03 PM UTC
SAN JOSE, Calif., June 17, 2024 In a significant stride towards revolutionizing urological care, PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a pioneering surgical robotics company, proudly announced today that the American Medical Association (AMA) has established a new Current Procedural Terminology (CPT) Category I code for its groundbreaking Aquablation therapy. Thi...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.11 $ |
| Revenues (TTM) |
5.68 $
|
| Cash Flow (TTM) |
- |
| Cash |
4.35 $
|
| Book Value |
6.15 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
361,500 |
| Net
Income per Employee (TTM) |
-115,398 |
| Receivable Turnover Ratio (TTM) |
3.72 |
| Inventory Turnover Ratio (TTM) |
1.63 |
| Asset Turnover Ratio (TTM) |
0.64 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.11 $
|
| Revenues (TTM) |
5.68 $ |
| Cash Flow (TTM) |
- |
| Cash |
4.35 $
|
| Book Value |
6.15 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| U S |
|
 86.82 % |
of total Revenue |
| Outside of U S |
|
13.4 % |
of total Revenue |
| System sales and rentals U S |
|
28.19 % |
of total Revenue |
| System sales and rentals Outside of U S |
|
4.65 % |
of total Revenue |
| Handpieces and other consumables U S |
|
51.86 % |
of total Revenue |
| Handpieces and other consumables Outside of U S |
|
7.68 % |
of total Revenue |
| Service U S |
|
6.77 % |
of total Revenue |
| Service Outside of U S |
|
1.07 % |
of total Revenue |
| United States |
|
0 % |
of total Revenue |
| Outside the United States |
|
0 % |
of total Revenue |
| |
On October 28 2024 the Procept Biorobotics provided following guidance
nnPROCEPT BioRobotics Corporation Announces Third Quarter 2024 Financial Results and Raises Revenue and Adjusted EBITDA Outlook for the Yearnn
nnSAN JOSE, Calif., October 28, 2024nn – PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a pioneering company in the field of surgical robotics dedicated to enhancing patient care through innovative urological solutions, has released its unaudited financial results for the third quarter of 2024, concluding on September 30, 2024.
In this latest update, the company has revealed that it is adjusting its projections for 2024, increasing both its anticipated revenue and adjusted EBITDA figures. While specific numbers were not disclosed in this communica...
|
|
|
0.27% 